Abstract
Psilocybin (a classic serotonergic psychedelic drug) has received appraisal for use in psychedelic-assisted therapy of several psychiatric disorders. A less explored topic concerns the use of repeated low doses of psychedelics, at a dose that is well below the psychedelic dose used in psychedelic-assisted therapy and often referred to as microdosing. Psilocybin microdose users frequently report increases in mental health, yet such reports are often highly biased and vulnerable to placebo effects. Here we establish and validate a psilocybin microdose-like regimen in rats with repeated low doses of psilocybin administration at a dose derived from occupancy at rat brain 5-HT2A receptors in vivo. The rats tolerated the repeated low doses of psilocybin well and did not manifest signs of anhedonia, anxiety, or altered locomotor activity. There were no deficits in pre-pulse inhibition of the startle reflex, nor did the treatment downregulate or desensitize the 5-HT2A receptors. However, the repeated low doses of psilocybin imparted resilience against the stress of multiple subcutaneous injections, and reduced the frequency of self-grooming, a proxy for human compulsive actions, while also increasing 5-HT7 receptor expression and synaptic density in the paraventricular nucleus of the thalamus. These results establish a well-validated regimen for further experiments probing the effects of repeated low doses of psilocybin. Results further substantiate anecdotal reports of the benefits of psilocybin microdosing as a therapeutic intervention, while pointing to a possible physiological mechanism.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Data availability
All data and statistical analysis, can be found at our Open Science Framework website https://osf.io/gy6m9/.
References
Agin-Liebes GI, Malone T, Yalch MM, Mennenga SE, Ponté KL, Guss J, et al. Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. J Psychopharmacol. 2020;34:155–66.
Johnson MW, Garcia-Romeu A, Griffiths RR. Long-term follow-up of psilocybin-facilitated smoking cessation. Am J Drug Alcohol Abus. 2017;43:55–60.
Goodwin GM, Aaronson ST, Alvarez O, Arden PC, Baker A, Bennett JC, et al. Single-dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med. 2022;387:1637–48.
Gukasyan N, Davis AK, Barrett FS, Cosimano MP, Sepeda ND, Johnson MW, et al. Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: prospective 12-month follow-up. J Psychopharmacol. 2022;36:151–8.
Fadiman J, Korb S. Might microdosing psychedelics be safe and beneficial? An initial exploration. J Psychoact Drugs. 2019;51:118–22.
Polito V, Liknaitzky P. The emerging science of microdosing: a systematic review of research on low dose psychedelics (1955-2021) and recommendations for the field. Neurosci Biobehav Rev. 2022;139:104706.
Andersson M. Twenty percent better with 20 micrograms? A qualitative study of psychedelic microdosing self-rapports and discussions on YouTube. Harm Reduct J. 2019;16:12.
Meade E, Hehir S, Rowan N, Garvey M. Mycotherapy: potential of fungal bioactives for the treatment of mental health disorders and morbidities of chronic pain. J Fungi. 2022;8:290.
Szigeti B, Kartner L, Blemings A, Rosas F, Feilding A, Nutt DJ, et al. Self-blinding citizen science to explore psychedelic microdosing. Elife. 2021;10:e62878.
Kuypers KP, Ng L, Erritzoe D, Knudsen GM, Nichols CD, Nichols DE, et al. Microdosing psychedelics: More questions than answers? An overview and suggestions for future research. J Psychopharmacol. 2019;33:1039–57.
Madsen MK, Fisher PM, Burmester D, Dyssegaard A, Stenbæk DS, Kristiansen S, et al. Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. Neuropsychopharmacology. 2019;44:1328–34.
Dinis-Oliveira RJ. Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance. Drug Metab Rev. 2017;49:84–91.
Kim K, Che T, Panova O, DiBerto JF, Lyu J, Krumm BE, et al. Structure of a hallucinogen-activated Gq-coupled 5-HT2A serotonin receptor. Cell. 2020;182:1574–1588.e19.
Rickli A, Moning OD, Hoener MC, Liechti ME. Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens. Eur Neuropsychopharmacol. 2016;26:1327–37.
Halberstadt AL, Geyer MA. Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology. 2011;61:364–81.
Herth MM, Debus F, Piel M, Palner M, Knudsen GM, Lüddens H, et al. Total synthesis and evaluation of [18F]MHMZ. Bioorg Med Chem Lett. 2008;18:1515–9.
Herth MM, Kramer V, Piel M, Palner M, Riss PJ, Knudsen GM, et al. Synthesis and in vitro affinities of various MDL 100907 derivatives as potential 18F-radioligands for 5-HT2A receptor imaging with PET. Bioorg Med Chem. 2009;17:2989–3002.
S. H. Keller, E. N. L'Estrade, B. Dall, M. Palner & M. Herth. Quantification accuracy of a new HRRT high throughput rat hotel using transmission-based attenuation correction: A phantom study, 2016 IEEE Nuclear Science Symposium, Medical Imaging Conference and Room-Temperature Semiconductor Detector Workshop (NSS/MIC/RTSD), Strasbourg, France, 2016, pp. 1–3, https://doi.org/10.1109/NSSMIC.2016.8069467.
Sureau FC, Reader AJ, Comtat C, Leroy C, Ribeiro M-J, Buvat I, et al. Impact of image-space resolution modeling for studies with the high-resolution research tomograph. J Nucl Med. 2008;49:1000–8.
Tantawy MN, Jones CK, Baldwin RM, Ansari MS, Conn PJ, Kessler RM, et al. [(18)F]Fallypride dopamine D2 receptor studies using delayed microPET scans and a modified Logan plot. Nucl Med Biol. 2009;36:931–40.
Jensen AA, McCorvy JD, Leth-Petersen S, Bundgaard C, Liebscher G, Kenakin TP, et al. Detailed characterization of the in vitro pharmacological and pharmacokinetic properties of N-(2-Hydroxybenzyl)-2,5-Dimethoxy-4-Cyanophenylethylamine (25CN-NBOH), a highly selective and brain-penetrant 5-HT2A receptor agonist. J Pharm Exp Ther. 2017;361:441–53.
Jensen AA, Plath N, Pedersen MHF, Isberg V, Krall J, Wellendorph P, et al. Design, synthesis, and pharmacological characterization of N- and O-substituted 5,6,7,8-tetrahydro-4H-isoxazolo[4,5-d]azepin-3-ol analogues: novel 5-HT(2A)/5-HT(2C) receptor agonists with pro-cognitive properties. J Med Chem. 2013;56:1211–27.
Casado-Sainz A, Gudmundsen F, Baerentzen SL, Lange D, Ringsted A, Martinez-Tejada I, et al. Dorsal striatal dopamine induces fronto-cortical hypoactivity and attenuates anxiety and compulsive behaviors in rats. Neuropsychopharmacology. 2022;47:454–64.
Halberstadt AL, Chatha M, Klein AK, Wallach J, Brandt SD. Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species. Neuropharmacology. 2020;167:107933.
Marona-Lewicka D, Nichols CD, Nichols DE. An animal model of schizophrenia based on chronic LSD administration: Old idea, new results. Neuropharmacology. 2011;61:503–12.
Liu M-Y, Yin C-Y, Zhu L-J, Zhu X-H, Xu C, Luo C-X, et al. Sucrose preference test for measurement of stress-induced anhedonia in mice. Nat Protoc. 2018;13:1686–98.
Kalueff AV, Stewart AM, Song C, Berridge KC, Graybiel AM, Fentress JC. Neurobiology of rodent self-grooming and its value for translational neuroscience. Nat Rev Neurosci. 2016;17:45–59.
Kalueff AV, Tuohimaa P. The grooming analysis algorithm discriminates between different levels of anxiety in rats: potential utility for neurobehavioural stress research. J Neurosci Methods. 2005;143:169–77.
Vollenweider FX, Csomor PA, Knappe B, Geyer MA, Quednow BB. The effects of the preferential 5-HT2A agonist psilocybin on pre-pulse inhibition of startle in healthy human volunteers depend on interstimulus interval. Neuropsychopharmacol. 2007;32:1876–87.
Tylš F, Páleníček T, Kadeřábek L, Lipski M, Kubešová A, Horáček J. Sex differences and serotonergic mechanisms in the behavioural effects of psilocin. Behav Pharm. 2016;27:309–20.
Halberstadt AL, Geyer MA. Serotonergic hallucinogens as translational models relevant to schizophrenia. Int J Neuropsychopharmacol. 2013;16:2165–80.
Raval NR, Johansen A, Donovan LL, Ros NF, Ozenne B, Hansen HD, et al. A single dose of psilocybin increases synaptic density and decreases 5-HT2A receptor density in the pig brain. Int J Mol Sci. 2021;22:835.
Shao L-X, Liao C, Gregg I, Davoudian PA, Savalia NK, Delagarza K, et al. Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. Neuron. 2021;109:2535–2544.e4.
Cavanna F, Muller S, de la Fuente LA, Zamberlan F, Palmucci M, Janeckova L, et al. Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study. Transl Psychiatry. 2022;12:1–11.
Horsley RR, Páleníček T, Kolin J, Valeš K. Psilocin and ketamine microdosing: effects of subchronic intermittent microdoses in the elevated plus-maze in male Wistar rats. Behav Pharm. 2018;29:530–6.
Cameron LP, Benson CJ, DeFelice BC, Fiehn O, Olson DE. Chronic, intermittent microdoses of the psychedelic N,N-dimethyltryptamine (DMT) produce positive effects on mood and anxiety in rodents. ACS Chem Neurosci. 2019;10:3261–70.
Lea T, Amada N, Jungaberle H, Schecke H, Scherbaum N, Klein M. Perceived outcomes of psychedelic microdosing as self-managed therapies for mental and substance use disorders. Psychopharmacology. 2020;237:1521–32.
Anderson T, Petranker R, Rosenbaum D, Weissman CR, Dinh-Williams L-A, Hui K, et al. Microdosing psychedelics: personality, mental health, and creativity differences in microdosers. Psychopharmacology. 2019;236:731–40.
Rosenbaum D, Weissman C, Anderson T, Petranker R, Dinh-Williams L-A, Hui K, et al. Microdosing psychedelics: Demographics, practices, and psychiatric comorbidities. J Psychopharmacol. 2020;34:612–22.
Ahmari SE, Spellman T, Douglass NL, Kheirbek MA, Simpson HB, Deisseroth K, et al. Repeated cortico-striatal stimulation generates persistent OCD-like behavior. Science. 2013;340:1234–9.
Lugo-Radillo A, Cortes-Lopez JL. Long-term amelioration of OCD symptoms in a patient with chronic consumption of psilocybin-containing mushrooms. J Psychoactive Drugs. 2020;53:146–8.
Moreno FA, Wiegand CB, Taitano EK, Delgado PL. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry. 2006;67:1735–40.
Gouzoulis-Mayfrank E, Heekeren K, Thelen B, Lindenblatt H, Kovar KA, Sass H, et al. Effects of the hallucinogen psilocybin on habituation and pre-pulse inhibition of the startle reflex in humans. Behav Pharm. 1998;9:561–6.
Hutten NRPW, Mason NL, Dolder PC, Kuypers KPC. Self-rated effectiveness of microdosing with psychedelics for mental and physical health problems among microdosers. Front Psychiatry. 2019;10:672.
Tokarski K, Kusek M, Hess G. 5-HT7 receptors modulate GABAergic transmission in rat hippocampal CA1 area. J Physiol Pharm. 2011;62:535–40.
Andressen KW, Manfra O, Brevik CH, Ulsund AH, Vanhoenacker P, Levy FO, et al. The atypical antipsychotics clozapine and olanzapine promote down-regulation and display functional selectivity at human 5-HT7 receptors. Br J Pharm. 2015;172:3846–60.
Okada M, Matsumoto R, Yamamoto Y, Fukuyama K. Effects of subchronic administrations of vortioxetine, lurasidone, and escitalopram on thalamocortical glutamatergic transmission associated with serotonin 5-HT7 receptor. Int J Mol Sci. 2021;22:1351.
Monti JM, Jantos H. The role of serotonin 5-HT7 receptor in regulating sleep and wakefulness. Rev Neurosci. 2014;25:429–37.
Ye Q, Nunez J, Zhang X. Raphe serotonin projections dynamically regulate feeding behavior through targeting inhibitory circuits from rostral zona incerta to paraventricular thalamus. Mol Metab. 2022;66:101634.
Kark SM, Birnie MT, Baram TZ, Yassa MA. Functional connectivity of the human paraventricular thalamic nucleus: insights from high field functional MRI. Front Integr Neurosci. 2021;15:662293.
Iglesias AG, Flagel SB. The paraventricular thalamus as a critical node of motivated behavior via the hypothalamic-thalamic-striatal circuit. Front Integr Neurosci. 2021;15:706713.
Castro-Alamancos MA, Calcagnotto ME. Presynaptic long-term potentiation in corticothalamic synapses. J Neurosci. 1999;19:9090–7.
Kelley AE, Baldo BA, Pratt WE. A proposed hypothalamic–thalamic–striatal axis for the integration of energy balance, arousal, and food reward. J Comp Neurol. 2005;493:72–85.
Choi EA, Jean-Richard-Dit-Bressel P, Clifford CWG, McNally GP. Paraventricular thalamus controls behavior during motivational conflict. J Neurosci. 2019;39:4945–58.
Kaertner LS, Steinborn MB, Kettner H, Spriggs MJ, Roseman L, Buchborn T, et al. Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing. Sci Rep. 2021;11:1941.
Acknowledgements
Psilocybin and psilocin were kindly provided by Prof. Dr. Tomáš Páleníček (Prague Psychiatric Center) and [3H]Cimbi-36 by Prof. Dr. Christer Halldin (Karolinska Institute). Professor DM Gitte M. Knudsen, head of the Neurobiology Research Unit, Copenhagen University Hospital, offered her support and guidance for students and researchers throughout the project.
Funding
Lundbeck Foundation (R192-2015-1591). Lundbeck Foundation (R194-2015-1589). Independent Research Fund Denmark (5053-00036B), Independent Research Fund Denmark (0169-00030B), Savværksejer Jeppe Juhls og Hustrus Ovita Juhls Mindelegat. Købmand i Odense Johann og Hanne Weimann født Seedorffs Legat.
Author information
Authors and Affiliations
Contributions
Conceptualization: JL, AO, MP. Methodology: KFK, JL, NSJ, TGB, JC, MS, NS, MX, WR, NRR, AC, VS, CK, GS, AB, AAJ, MMH, MP. Investigation: KFK, JL, NSJ, TGB, JC, MS, NS, MX, WR, NRR, AC, VS, GS, AB, AAJ, MMH, MP. Visualization: MP. Funding acquisition: MP. Project administration: MP. Supervision: NRR, CK, MMH, AO, MP. Writing – original draft: KFK, JL, PC, MP. Writing – review & editing: KFK, JL, NSJ, TGB, JC, MS, NS, MX, WR, NRR, AC, VS, GS, CK, AB, AAJ, MMH, PC, AO, MP.
Corresponding author
Ethics declarations
Competing interests
MP has an ongoing research collaboration with Compass Pathways LTD and holds stock in Compass Pathways LTD. AAJ is co-founder and co-owner of the company Lophora ApS. The other authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Kiilerich, K.F., Lorenz, J., Scharff, M.B. et al. Repeated low doses of psilocybin increase resilience to stress, lower compulsive actions, and strengthen cortical connections to the paraventricular thalamic nucleus in rats. Mol Psychiatry 28, 3829–3841 (2023). https://doi.org/10.1038/s41380-023-02280-z
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41380-023-02280-z